Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Teijin Pharma, Amgen Ink License Pact on Kidney Diseases
December 21, 2016
- New Technologies to Cure Cancers, Help Reduce Medical Expenditure: Report
December 21, 2016
- Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
December 20, 2016
- AZ, NCC Ink Collaboration on Biomarkers for Lung Cancer Immunotherapy
December 20, 2016
- Hisamitsu Seeks Japan Approval for Allergic Rhinitis Tape Treatment
December 20, 2016
- Shionogi Hooks Up with Purdue on Naldemedine Commercialization in US
December 20, 2016
- Concerns Expressed Over High Cost of Regenerative Medicines; As with Opdivo, “Bound to Become Issue Again”
December 20, 2016
- Teva Takeda Recalls Dalteparin “Taiyo”
December 20, 2016
- Japan Osteoporosis Market to Expand 45.3% by 2024: Fuji Keizai
December 19, 2016
- Public Knowledge-Based Application Filed for Tamiflu’s New Pediatric Dosage
December 19, 2016
- Fujifilm Allies with Russia’s R-Pharm in Healthcare
December 19, 2016
- Otsuka Gets Exclusive Rights to Takara Bio’s Oncolytic Virus in Japan
December 16, 2016
- Continued Xtandi Treatment Fails to Extend PFS: US PIV Trial
December 16, 2016
- Belsomra Most Heavily Promoted Drug in HP Market October: Anterio
December 16, 2016
- Sysmex, Astellas, and Daiichi Sankyo Ink Memo to Create Method for Analyzing CTC
December 16, 2016
- Diovan Data Manipulation Case Closed, Ruling Due Out in March
December 16, 2016
- Shinjiro Sato Tapped as Next President of Terumo
December 16, 2016
- Aspen Japan, Kissei Sign Copromotion Pact on Imuran
December 16, 2016
- Fujifilm to Acquire Takeda’s Reagent Unit for 155 Billion Yen
December 16, 2016
- Nippon Kayaku Introduces “MSLs” to Strengthen Detailing for Oncology Generics, Biosimilars, and Products in Development
December 16, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…